New Guidance for Managing Obesity in Patients with Kidney Disease

Multidisciplinary Care and Sensitivity Key to Obesity Management in Kidney Disease

A new report from the American Society of Nephrology (ASN) offers updated guidance on the management of obesity in patients with kidney disease, emphasizing the importance of a tailored, multidisciplinary approach. The guidance, developed by Dr. T. Alp Ikizler and colleagues from Vanderbilt University Medical Center, was published in the Journal of the American Society of Nephrology on September 18, 2024.

Expanding Treatment Options and Addressing Gaps in Care

The report highlights the dual benefits of obesity management for kidney disease patients. Weight loss not only enhances mood and quality of life but can also slow the progression of kidney disease. Despite these advantages, effective management remains complex and necessitates the involvement of a multidisciplinary team. The guidance prioritizes lifestyle modification as the first-line treatment, irrespective of other interventions. The use of antiobesity medications, particularly incretin mimetics, is recommended as a safe and effective option for patients with kidney disease.

Additionally, while metabolic and bariatric surgery have historically been underused in this population, evidence suggests that kidney disease should not be viewed as a contraindication to these procedures. The guidance also calls for addressing gaps in knowledge, particularly concerning the long-term effects of these interventions in kidney disease patients.

Improving Patient Outcomes and Quality of Life

Managing obesity in individuals with kidney disease is not just about improving physical health. This new guidance underscores the need to address psychosocial factors, including mental health comorbidities, past experiences with discrimination, and social determinants of health. By approaching treatment with sensitivity and a personalized care plan, healthcare professionals can improve both the physical and emotional well-being of their patients. This is particularly crucial as obesity management has been shown to slow the progression of kidney disease, offering patients better long-term outcomes and quality of life.

The report encourages clinicians to remain vigilant in closing the knowledge gaps in this area, as further research will enhance care strategies and improve the lives of patients living with both obesity and kidney disease.